ARGX argenx SE

149.23
-4.28  -3%
Previous Close 153.51
Open 151.9
Price To Book 8.61
Market Cap 6,375,407,492
Shares 42,722,023
Volume 91,685
Short Ratio
Av. Daily Volume 180,959
Stock charts supplied by TradingView

NewsSee all news

  1. argenx announces closing of global offering

    Regulated information – Inside information November 12, 2019 - 10:00 PM CET Breda, the Netherlands / Ghent, Belgium – argenx ((Euronext &, NASDAQ:ARGX) a clinical-stage biotechnology company developing a deep

  2. argenx announces full exercise of underwriters' option to purchase additional ADSs

    Regulated information – Inside information November 8, 2019, 7:00 AM CET Breda, the Netherlands / Ghent, Belgium – argenx ((Euronext &, NASDAQ:ARGX), a clinical-stage biotechnology company developing a deep

  3. argenx raises $484 million in gross proceeds in a global offering

    Regulated information – Inside information November 6, 2019, 10:45 PM ESTNovember 7, 2019, 04:45 AM CET Breda, the Netherlands / Ghent, Belgium – argenx ((Euronext &, NASDAQ:ARGX), a clinical-stage biotechnology

  4. argenx to Present at Morgan Stanley 17th Annual Global Healthcare Conference

    September 3, 2019 Breda, the Netherlands / Ghent, Belgium – argenx ((Euronext &, NASDAQ:ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due 1H 2020.
Efgartigimod (ARGX-113)
Pemphigus vulgaris (PV)
Phase 2 presentation at ASH December 2018.
ARGX-110
Relapsed/refractory cutaneous T-cell lymphoma (CTCL)
Phase 2 update due 2020.
Cusatuzumab (ARGX-110)
Acute myeloid leukemia (AML)
Phase 3 trial initiated December 2019.
Efgartigimod (ARGX-113)
Immune thrombocytopenia (ITP)
Phase 3 data due mid-2020.
Efgartigimod (ARGX-113)
Myasthenia gravis (MG)
Phase 1 trial to commence 1Q 2020.
ARGX-117
Autoimmune diseases
Phase 1 data due YE 2019. Moved to 1Q 2020 due to no update.
Efgartigimod (ARGX-113) and Enhanze
Healthy volunteers
Phase 2 trial has been initiated - noted January 9, 2020.
Efgartigimod (ARGX-113)
Chronic inflammatory demyelinating polyneuropathy

Latest News

  1. argenx announces closing of global offering

    Regulated information – Inside information November 12, 2019 - 10:00 PM CET Breda, the Netherlands / Ghent, Belgium – argenx ((Euronext &, NASDAQ:ARGX) a clinical-stage biotechnology company developing a deep

  2. argenx announces full exercise of underwriters' option to purchase additional ADSs

    Regulated information – Inside information November 8, 2019, 7:00 AM CET Breda, the Netherlands / Ghent, Belgium – argenx ((Euronext &, NASDAQ:ARGX), a clinical-stage biotechnology company developing a deep

  3. argenx raises $484 million in gross proceeds in a global offering

    Regulated information – Inside information November 6, 2019, 10:45 PM ESTNovember 7, 2019, 04:45 AM CET Breda, the Netherlands / Ghent, Belgium – argenx ((Euronext &, NASDAQ:ARGX), a clinical-stage biotechnology

  4. argenx to Present at Morgan Stanley 17th Annual Global Healthcare Conference

    September 3, 2019 Breda, the Netherlands / Ghent, Belgium – argenx ((Euronext &, NASDAQ:ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the